These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36971841)

  • 1. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).
    Swallow DMA; Counsell CE
    J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.
    Constantinides VC; Souvatzoglou M; Paraskevas GP; Chalioti M; Stefanis L; Kapaki E
    Neurol Sci; 2023 May; 44(5):1613-1623. PubMed ID: 36658411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome.
    Giannoccaro MP; Avoni P; Rizzo G; Incensi A; Infante R; Donadio V; Liguori R
    J Parkinsons Dis; 2022; 12(2):585-591. PubMed ID: 34864689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
    Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
    J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism.
    Yoon WT
    Neurol Neurochir Pol; 2018; 52(1):48-53. PubMed ID: 29196058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients.
    Toyoshima Y; Takahashi H; Katada S; Kojima N; Tada M; Tani T; Koike R; Nozawa T; Aida I; Nakajima T; Onodera O; Kakita A
    Neuropathology; 2021 Dec; 41(6):450-456. PubMed ID: 34779072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of falls in postmortem-confirmed parkinsonian disorders.
    Wenning GK; Ebersbach G; Verny M; Chaudhuri KR; Jellinger K; McKee A; Poewe W; Litvan I
    Mov Disord; 1999 Nov; 14(6):947-50. PubMed ID: 10584668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.
    Badoud S; Van De Ville D; Nicastro N; Garibotto V; Burkhard PR; Haller S
    Neuroimage Clin; 2016; 12():234-40. PubMed ID: 27489771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
    Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
    Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Quattrone A; Bianco MG; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Tedeschi G; Tessitore A; Cilia R; Morelli M; Nigro S; Vescio B; Arcuri PP; De Micco R; Cirillo M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2022 Jun; 37(6):1272-1281. PubMed ID: 35403258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease.
    Miyata M; Kakeda S; Toyoshima Y; Ide S; Okada K; Adachi H; Wang Y; Korogi Y
    Neuroradiology; 2019 Nov; 61(11):1251-1259. PubMed ID: 31267152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW
    Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients.
    Sankhla CS; Patil KB; Sawant N; Gupta S
    Neurol India; 2016; 64(2):239-45. PubMed ID: 26954800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Illán-Gala I; Nigro S; VandeVrede L; Falgàs N; Heuer HW; Painous C; Compta Y; Martí MJ; Montal V; Pagonabarraga J; Kulisevsky J; Lleó A; Fortea J; Logroscino G; Quattrone A; Quattrone A; Perry DC; Gorno-Tempini ML; Rosen HJ; Grinberg LT; Spina S; La Joie R; Rabinovici GD; Miller BL; Rojas JC; Seeley WW; Boxer AL
    JAMA Netw Open; 2022 Apr; 5(4):e229588. PubMed ID: 35486397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive Supranuclear Palsy and Corticobasal Syndrome.
    Pantelyat A
    Continuum (Minneap Minn); 2022 Oct; 28(5):1364-1378. PubMed ID: 36222770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers.
    Parmera JB; Oliveira MCB; Rodrigues RD; Coutinho AM
    Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):126-136. PubMed ID: 35976324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration.
    Gröschel K; Hauser TK; Luft A; Patronas N; Dichgans J; Litvan I; Schulz JB
    Neuroimage; 2004 Feb; 21(2):714-24. PubMed ID: 14980574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.